Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Austria Accepts Merck Commitments After ‘Predatory Pricing’ Undermined Generics

Merck Found To Have An 85% Share Of The Temozolomide Market

Executive Summary

Merck has agreed to discontinue a “predatory strategy” for the company’s Temodal (temozolomide) oncology brand in Austria that kept generics out of the market, including by supplying the brand below cost price, under commitments offered to the country’s competition watchdog.

You may also be interested in...



EU Investigates Teva For Undermining Copaxone Generics

The European Commission is investigating whether Teva “abusively” blocked or delayed market entry of competitors to the company’s top selling multiple sclerosis drug.

EU Accepts Aspen Price Commitments

Commitments offered by Aspen Pharmacare last year to settle price-gouging allegations over six oncology drugs have been accepted by the European Commission.

Aspen Will Pay UK's NHS £8m In Landmark Deal Following Competition Probe

Aspen has agreed to pay the National Health Service £8m following an investigation by the Competition and Markets Authority.

Topics

Related Companies

UsernamePublicRestriction

Register

GB150821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel